Skip to main content
SpringerLink
Log in

Gliflozine außerhalb des Diabetes

SGLT-2-Inhibition verbessert renale Endpunkte auch bei Nichtdiabetikern

  • Journal club
  • Published:
Info Diabetologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-28

  2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-57

  3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine 2019; 380: 347-57

  4. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019;

  5. Dumann E, Haller H, Menne J. SGLT2-Inhibitoren bei diabetischer Nephropathie. Der Nephrologe 2020; 15: 153-62

Download references

Author information

Authors and Affiliations

  1. Nephrolog. Gemeinschaftspraxis Dr. Link\/Prof. P. Weyrich, Hauptstraße 2, 82008, Unterhaching, Deutschland

    Peter Weyrich

Authors
  1. Peter Weyrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Weyrich.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weyrich, P. SGLT-2-Inhibition verbessert renale Endpunkte auch bei Nichtdiabetikern. Info Diabetol 14, 18–20 (2020). https://doi.org/10.1007/s15034-020-2217-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15034-020-2217-8

Search

Navigation